Biologicals Join List Of EU Medicines Requiring Nitrosamine Evaluation
Executive Summary
Although biological medicines carry a very low risk of being contaminated by nitrosamine impurities, the EMA says the possibility cannot be ruled out.
You may also be interested in...
EU Allows Firms More Time To Make Nitrosamine-Related Manufacturing Changes
The European medicines regulatory network is giving sponsors of marketed medicines that contain chemically synthesised active substances an extra 12 months to apply for manufacturing changes to address nitrosamine-related risks.
EU Allows Firms More Time To Make Nitrosamine-Related Manufacturing Changes
The European medicines regulatory network is giving sponsors of marketed medicines that contain chemically synthesised active substances an extra 12 months to apply for manufacturing changes to address nitrosamine-related risks.
EU Nitrosamines Oversight Group Sets Priorities
After agreeing on an EU-wide harmonized approach to deal with nitrosamine contamination in medicines, a recently formed regulatory oversight group has identified several topics requiring further scientific discussion.